• 1. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Distinct impact of glycation towards the aggregation and toxicity of murine and human amyloid-β?
  Eunju Nam,Jiyeon Han,Sunhee Choi,Mi Hee Lim Chem. Commun., 2021,57, 7637-7640
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Research Brief on 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine (CAS: 183208-54-0)

1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine (CAS: 183208-54-0) is a brominated pyrrolopyridine derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly those targeting protein kinases and other signaling pathways implicated in cancer and inflammatory diseases. Recent studies have explored its utility in the development of novel therapeutic agents, leveraging its unique chemical structure to modulate specific biological targets.

The compound's molecular framework, featuring a 5-bromo-1H-pyrrolo[2,3-b]pyridine core and a dimethylaminoethyl side chain, offers versatility in medicinal chemistry applications. Recent research has focused on its role as a building block for small-molecule inhibitors, particularly in the context of kinase inhibition. For instance, derivatives of this compound have shown promising activity against JAK (Janus kinase) family members, which are critical in cytokine signaling and immune regulation. These findings underscore its potential as a scaffold for designing next-generation kinase inhibitors with improved selectivity and pharmacokinetic properties.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine as a precursor to develop a series of JAK3 inhibitors. The study demonstrated that modifications at the 5-bromo position and the dimethylamino group could significantly alter the compound's binding affinity and selectivity. Molecular docking simulations revealed that the bromine atom plays a crucial role in forming hydrophobic interactions with the kinase's ATP-binding pocket, while the dimethylamino group contributes to solubility and cellular permeability. These insights have paved the way for optimizing this scaffold for clinical applications.

Another area of interest is the compound's potential in targeted protein degradation (TPD) strategies, such as PROTACs (Proteolysis-Targeting Chimeras). A 2022 study in ACS Chemical Biology reported the incorporation of 183208-54-0 into a PROTAC molecule designed to degrade BET (bromodomain and extra-terminal) proteins. The brominated pyrrolopyridine moiety served as a warhead to bind BET proteins, while the dimethylamino group facilitated linker attachment to an E3 ligase recruiter. This approach resulted in potent degradation of target proteins in cancer cell lines, highlighting the compound's utility in emerging therapeutic modalities.

From a synthetic chemistry perspective, recent advancements have focused on improving the scalability and efficiency of producing 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine. A 2023 Organic Process Research & Development publication detailed a novel catalytic system for the bromination of pyrrolopyridine derivatives, achieving higher yields and reduced byproduct formation compared to traditional methods. This development is critical for ensuring a reliable supply chain for drug discovery efforts leveraging this compound.

In conclusion, 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N,N-dimethylmethanamine (183208-54-0) represents a versatile and pharmacologically relevant scaffold in modern drug discovery. Its applications span from traditional kinase inhibition to innovative protein degradation strategies, supported by ongoing research into its structure-activity relationships and synthetic accessibility. As the field of targeted therapies continues to evolve, this compound is likely to remain a valuable tool for medicinal chemists and pharmacologists alike.

• 1111637-94-5(5-Bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine)
• 1638768-00-9((2-{5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl}ethyl)dimethylamine)
• 5654-92-2(dimethyl({1H-pyrrolo[2,3-b]pyridin-3-ylmethyl})amine)
• 1056135-40-0(1H-Pyrrolo[2,3-b]pyridine-3-methanamine, 6-bromo-N,N-dimethyl-)
• 87358-28-9(N,N,N-Trimethyl(1H-pyrrolo[2,3-b]pyridin-3-yl)methanaminium iodide)
• 4894-31-9(1H-Pyrrolo[2,3-b]pyridine-3-methanamine, N,N,4-trimethyl-)
• 1198277-82-5(4-Bromo-N,N-dimethyl-1H-pyrrolo2,3-bpyridine-3-methanamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)